Finding new ways to help the immune system fight triple-negative breast cancer
Developing a novel therapeutic strategy for overcoming resistance to PD-1 blockade in Triple-negative breast cancer
This study is looking for ways to make treatments better for people with triple-negative breast cancer by finding new ways to help the immune system fight the cancer more effectively.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-11010798 on NIH RePORTER |
What this research studies
This research focuses on improving treatment for triple-negative breast cancer (TNBC), a type of cancer known for its aggressive nature and poor response to existing therapies. The team aims to enhance the effectiveness of PD-1 blockade therapy, which has shown limited success in TNBC patients. By investigating the role of specific immune cells and their interactions, the researchers hope to activate suppressed T cells, thereby boosting the immune response against the cancer. The study employs advanced techniques to understand the mechanisms behind immune suppression and seeks to develop novel therapeutic strategies to overcome these challenges.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer who have not responded well to current PD-1 blockade therapies.
Not a fit: Patients with non-triple-negative breast cancer or those who have already had successful responses to PD-1 therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with triple-negative breast cancer, potentially improving survival rates and quality of life.
How similar studies have performed: While there has been some success in using immune checkpoint inhibitors in other cancers, this specific approach to enhance PD-1 blockade in TNBC is relatively novel and has not been extensively tested.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Zhang, Chunyan — Beckman Research Institute/city of Hope
- Study coordinator: Zhang, Chunyan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.